Cytokinetics | Beneficio Bruto En Ventas



Gross Profit On Sales Cambio Fecha
Acadia Pharmaceuticals USD 237.8M 72.86M 2024-12
Amgen USD 5.97B 781M 2024-12
Bayer EUR 6.01B 1.13B 2024-12
Biogen USD 1.87B 44.1M 2024-12
Bristol-Myers Squibb USD 9.13B 94M 2024-12
Cytokinetics -160545000 81.19M 2024-09
Eisai JPY 170.21B 16.72B 2024-12
Eli Lilly USD 11.13B 1.86B 2024-12
Exelixis USD 546.79M 24.58M 2025-01
Geron 46.75M 18.94M 2024-12
Halozyme Therapeutics USD 255.95M 15.3M 2024-12
Intra Cellular Therapies USD 178.82M 18.75M 2024-12
Ionis Pharmaceuticals USD 222.75M 90M 2024-12
Ligand Pharmaceuticals USD 39.98M 9.39M 2024-12
Merck USD 11.92B 852M 2024-12
Novartis USD 10.23B 294M 2024-12
Pfizer USD 12.11B 718M 2024-12
Regeneron Pharmaceuticals USD 3.22B 1.88B 2024-12
Roche Holding CHF 11.69B 48M 2024-12
Sanofi EUR 10.07B 2.1B 2024-09



Cytokinetics Beneficio Bruto En Ventas - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Mar 2025.